Topical Antimycotics for Oral Candidiasis in Warfarin Users

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Interactions

Background:

• Oral candidiasis treatment in warfarin patients is complex due to potential drug-drug interactions (DDIs).
• Existing data on DDIs between warfarin and topical antifungals are limited to case series.

Purpose of the Study:

• To evaluate potential DDIs between warfarin and miconazole oral gel or nystatin oral solution.
• To compare the safety and efficacy of miconazole versus nystatin in warfarin users.

Main Methods:

• A cohort cross-over study design was employed.
• International Normalized Ratio (INR) data from warfarin users (n ≈ 7400, 1998-2012) were analyzed.
• INR values before and after exposure to miconazole oral gel or nystatin oral solution were compared.

Main Results:

• Miconazole oral gel use was associated with a significant mean INR increase (1.4 units) in warfarin users.
• Nystatin oral solution use showed no significant change in mean INR among warfarin users.
• A clinically relevant DDI was identified between warfarin and miconazole oral gel.

Conclusions:

• Nystatin oral solution is a safer alternative to miconazole oral gel for treating oral candidiasis in warfarin patients.
• Clinicians should prefer nystatin over miconazole to avoid potential DDIs and manage INR levels effectively.
• This study provides evidence-based guidance for antifungal selection in anticoagulated patients.